Oncology Brothers have recently shared their highlights from SABCS23. Below we feature the first day’s highlights from X/Twitter.

”SABCS23 Day 1 Highlights Community Oncology:

FDA Oncology. Review on recent approvals

1. CAPItello291
2. EMERALD
3. TDxD
4. Tumor Agnostic landscape
5. Post CDK4/6i HR+

SABCS23 Day 1 Highlights by Oncology Brothers

1. Capivasertib approved on 11/16/23 w/ AKT pathway alteration based off: CAPItello291. Capi + Fulvestrant vs Fulvestrant + Placebo

– Higer PFS w/ capivasertib 7.2mos vs 3.6mos (HR 0.60),
– Pending OS,
– 400mg BID, 4days on/3days off.

For the more information click here.

2. Elacestrant approved on 1/27/23 based off: EMERAL w/ ESR1 mutation. Elacestrant vs Fulvestrant in 2nd L and beyond.

– mPFS improved w/ Elacestrant
most Benefit CDK4/6i >12mos,
– AE: musculoskeletal pain, nausea,
increased cholesterol.

For the more information click here.

3. TDxd approved for HR+ and TNBC with low Her2 on 8/5/22 based off: DB04

– mFU 32mos, OS 23.9mos vs 17.6 mos (in Hr+, HR: 0.69),
– OS 22.9mos vs 16.8mos (in All Pts, HR: 0.69).

For the more information click here.

SABCS23 Day 1 Highlights by Oncology Brothers

4. Tumor Agnostic landscape: 2017-22

– Pembro + Dostar in MSI-H. Pembro in High TMB,
– Larotrectinib + Entrectinib in NTRK,
– Dabrafenib/Trametinib in BRAF V600E,
– Selpercatinib in RET fusion.

For the more information click here.

SABCS23 Day 1 Highlights by Oncology Brothers

5. What to do post CDK4/6i: phenomenal session!

– PARPi, AKT pathway, ESR1 or ADCs, everolimus and chemo are potential options. Switch CDK4/6i Rx might be an option,
– Abigail Johnston, one of the most moving talks I have EVER heard!”

SABCS23 Day 1 Highlights by Oncology Brothers

Source: Oncology Brothers/X